EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies

Melissa T Bu iD, Long Yuan, Alyssa N Klee, Gordon J Freeman

Monoclonal Antibodies in Immunodiagnosis & Immunotherapy · 01.08.2022 · 41 (4) · 202-209

DOI: 10.1089/mab.2021.0068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, online erschienen am 25.08.2022. Verfasst von Melissa T Bu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model cancer immunotherapy in mouse models. We set forth the amino acid sequences of mAbs specific for mouse PD-1 (29F.1A12) and PD-L1 (10F.9G2) and compare their avidities, blocking capacities, biological activities, and epitope recognition with other commonly used mAbs. Further manipulation of these sequences should facilitate better modeling of immunotherapy in mouse models and the generation of novel agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalNeoplasmsAnimalsAntibodies, MonoclonalB7-H1 AntigenImmunotherapyMiceProgrammed Cell Death 1 ReceptorRats

Stichwörter der Autor:innen

PD-1PD-L1antibody sequencescancer immunotherapymonoclonal antibody

Substanzen

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalB7-H1 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Melissa T Bu

Förderung

  • NIAID NIH HHS

Zitieren

APA

Bu, M. T., Yuan, L., Klee, A. N., & Freeman, G. J. (2022). A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, 41(4), 202-209. https://doi.org/10.1089/mab.2021.0068

Vancouver

Bu MT, Yuan L, Klee AN, Freeman GJ. A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy. 2022;41(4):202-209. doi:10.1089/mab.2021.0068

BibTeX
@article{Bu2022,
  author = {Bu, Melissa T and Yuan, Long and Klee, Alyssa N and Freeman, Gordon J},
  title = {A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies},
  journal = {Monoclonal Antibodies in Immunodiagnosis & Immunotherapy},
  year = {2022},
  volume = {41},
  number = {4},
  pages = {202--209},
  doi = {10.1089/mab.2021.0068}
}
Kostenlos starten →